Arca
Skip to content

Medicaid Drug Spending

Medicaid, the health program for low-income Americans, is run by each state, and every state reports what it paid pharmacies for each drug. This adds those reports up by drug and by state, before the rebates drug makers pay back.

What state Medicaid programs paid pharmacies for 1,915 outpatient drugs in 2025, before manufacturer rebates, with prescriptions, the change from 2024 and each state's share, from CMS's State Drug Utilization Data.

  • Paid in 2025: $116.9B
  • Change from 2024: +8%
  • Prescriptions: 725M
  • Top drug: Ozempic, $3.8B
  • Since 2016: 78% more

Paid per Year

All outpatient drugs, before rebates.

Biggest Drugs, 2025

By amount paid, before rebates.

  • Ozempic$3.8B
  • Biktarvy$3.6B
  • Humira$3.5B
  • Dupixent$3.0B
  • Wegovy$2.6B
  • Jardiance$2.5B
  • Invega$2.4B
  • Trulicity$1.9B
  • Zepbound$1.8B
  • Skyrizi$1.8B

Biggest States, 2025

Fee-for-service and managed care together.

  • California$18.3B
  • New York$12.7B
  • Pennsylvania$5.4B
  • Ohio$4.8B
  • North Carolina$4.7B
  • Michigan$4.2B
  • Texas$3.7B
  • Illinois$3.3B
  • Florida$3.3B
  • Indiana$2.9B

Every Drug, 2025

Largest first; sort by change or cost per prescription, or search a drug.
Top state
Ozempic$3.75B3,695,710$1,016+11%California
Biktarvy$3.56B780,134$4,558+9%New York
Humira$3.49B386,973$9,020-17%California
Dupixent$3.04B765,585$3,974+29%New York
Wegovy$2.60B1,995,718$1,303+82%California
Jardiance$2.52B2,945,841$855+13%California
Invega$2.40B704,944$3,407+5%California
Trulicity$1.95B1,940,795$1,004-10%Ohio
Zepbound$1.81B1,723,702$1,049+534%California
Skyrizi$1.76B86,735$20,276+58%California
Vraylar$1.63B1,096,927$1,483+14%Ohio
Mounjaro$1.52B1,416,807$1,070+65%California
Trikafta$1.45B53,971$26,862-7%California
Cosentyx$1.43B154,503$9,252+19%California
Eliquis$1.42B2,188,265$650+10%California
Stelara$1.37B53,532$25,525-16%California
Enbrel$1.11B140,549$7,932+3%California
Vyvanse$1.08B2,886,437$375-4%Wisconsin
Abilify$1.03B367,670$2,800+13%California
Hemlibra$995.0M29,976$33,193+7%California
Keytruda$892.5M78,912$11,310+4%California
Farxiga$890.9M1,129,790$789+9%California
Rinvoq$833.7M111,488$7,478+44%California
Suboxone$814.8M2,354,516$346-9%Maryland
Symbicort$702.0M2,850,515$246+10%New York
Sublocade$687.3M343,837$1,999+26%Pennsylvania
Ingrezza$675.3M86,668$7,792+15%California
Nurtec$632.7M499,751$1,266+18%New York
Taltz$616.4M76,699$8,037+1%Pennsylvania
Mavyret$599.1M45,561$13,150-3%California
Linzess$586.6M924,006$635+22%California
Epidiolex$570.9M152,460$3,745+10%California
Trelegy$554.1M779,112$711+15%New York
Norditropi$547.8M93,747$5,843+42%New York
Fluticason$546.2M11,537,335$47-13%California
Entresto$546.1M666,978$819-13%New York
Tremfya$533.0M36,317$14,677+51%New York
Rexulti$525.8M351,599$1,495+12%Michigan
Austedo$512.7M66,688$7,688+31%California
Xarelto$469.6M666,827$704-4%California
Descovy$466.3M183,537$2,541-1%California
Ocrevus$451.4M14,870$30,355+6%New York
Kesimpta$447.6M44,144$10,139+34%California
Xolair$440.9M160,698$2,744+17%New York
Verzenio$439.9M28,782$15,285+10%California
Caplyta$426.8M256,826$1,662+35%California
Bimzelx$425.8M22,379$19,025+825%New York
Creon$422.0M211,510$1,995+5%New York
Insulin$400.7M2,598,418$154+19%New York
Evrysdi$399.0M15,567$25,628+15%California

States report every outpatient drug their Medicaid programs pay for under the Medicaid Drug Rebate Program, fee-for-service and managed care. Amounts are what pharmacies were paid, before the rebates manufacturers pay back to Medicaid, which are confidential per drug. CMS cuts product names to 10 characters, so a drug here is the first word of its name and strengths are added together. Counts under 11 are suppressed by CMS and left out. The current year appears once all four quarters are in. Refreshed weekly. CMS, State Drug Utilization Data

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.